Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › AL › Birmingham › NPI 1295726032
Lab

Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings was paid $289.12M by Medicaid between Jan 2018 and Dec 2024, across 509 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 7.3% of everything it billed.

33Billing provider infoLABORATORY CORPORATION OF AMERICA HOLDINGS
BIRMINGHAM, AL 35233
33aNPI1295726032assigned 11/01/2005
33bProvider typeClinical Medical Laboratory
28Total paid$289.12M
24GClaims29,662,567
24DCodes billed509
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Alabama

Rank by total paid#2 of 61
Median peer was paid$46K
This provider vs. median6,349×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$2.0M$4.0M$6.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20183,195,249$31.05M
20193,318,726$30.51M
20203,792,306$38.15M
20214,811,560$47.94M
20224,776,272$47.46M
20235,408,181$51.78M
2024incomplete4,360,273$42.22M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 7.3% 1,060,905 926,649 $21.16M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 7.1% 1,053,401 920,094 $20.59M
80050 General health panel 5.8% 789,061 696,368 $16.70M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 4.3% 738,701 655,136 $12.54M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 4.1% 42,226 36,376 $11.71M
80061 Lipid panel 3.9% 1,768,106 1,538,467 $11.33M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 3.9% 852,597 723,068 $11.29M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 3.6% 738,246 657,202 $10.34M
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 3.1% 129,095 113,563 $8.91M
80053 Comprehensive metabolic panel 3.0% 1,654,006 1,445,431 $8.70M
80081 2.5% 162,952 147,553 $7.12M
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 2.5% 483,727 443,938 $7.12M
497 more codes
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 2.3% 147,327 $6.73M
84443 Thyroid stimulating hormone (TSH) 2.2% 874,088 $6.50M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 2.2% 1,464,954 $6.45M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1.9% 168,852 $5.48M
83036 Hemoglobin; glycosylated (A1C) 1.9% 1,279,116 $5.39M
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 1.7% 23,266 $4.91M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.5% 259,385 $4.37M
87086 Culture, bacterial; quantitative colony count, urine 1.3% 840,820 $3.81M
80074 1.0% 164,586 $3.02M
86803 1.0% 387,761 $2.92M
87536 <1% 62,332 $2.69M
84439 <1% 640,037 $2.54M
82607 <1% 351,100 $2.46M
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 53,957 $2.41M
87150 <1% 140,121 $2.32M
86480 <1% 54,972 $1.77M
84403 <1% 133,629 $1.72M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 90,041 $1.70M
86235 <1% 32,698 $1.65M
82746 <1% 237,249 $1.53M
86592 <1% 611,710 $1.50M
87081 <1% 348,300 $1.47M
82728 <1% 252,911 $1.45M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 33,887 $1.44M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 29,189 $1.43M
80055 <1% 34,695 $1.36M
86696 <1% 114,018 $1.26M
87088 <1% 276,428 $1.22M
87186 <1% 237,695 $1.16M
82670 <1% 84,085 $1.15M
84153 <1% 136,606 $1.13M
84702 <1% 159,390 $1.08M
83001 <1% 108,929 $1.07M
83655 <1% 125,350 $1.07M
87340 <1% 189,869 $1.07M
87077 <1% 236,067 $1.02M
84146 <1% 97,141 $1.01M
83550 <1% 242,022 $967K
88142 <1% 63,216 $884K
86360 <1% 37,478 $880K
88141 <1% 74,415 $878K
87522 Neg quan hep c or qual rna <1% 41,607 $876K
86003 <1% 27,132 $859K
83002 <1% 88,462 $858K
84402 <1% 68,088 $851K
36415 Collection of venous blood by venipuncture <1% 505,878 $788K
87902 <1% 7,102 $786K
83970 <1% 49,553 $784K
82570 <1% 285,584 $783K
83540 <1% 281,715 $777K
86038 <1% 115,511 $754K
85027 <1% 256,063 $747K
86769 <1% 20,832 $735K
80048 Basic metabolic panel (calcium, ionized) <1% 176,276 $714K
86695 <1% 100,938 $708K
84481 <1% 96,675 $704K
82043 <1% 252,648 $694K
84144 <1% 65,124 $679K
84436 <1% 216,502 $627K
83013 <1% 19,343 $622K
87070 <1% 119,470 $616K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 32,240 $602K
82950 <1% 191,625 $601K
86780 <1% 72,755 $590K
81001 <1% 314,955 $544K
86762 <1% 62,133 $524K
82784 <1% 65,789 $523K
83735 <1% 153,387 $518K
83880 <1% 35,190 $512K
86850 <1% 82,240 $472K
86376 <1% 64,318 $458K
86140 <1% 169,858 $415K
86787 <1% 51,431 $412K
87901 <1% 3,283 $411K
84479 <1% 161,533 $409K
86706 <1% 70,055 $396K
84480 <1% 58,933 $392K
86665 <1% 19,003 $383K
83525 <1% 60,838 $381K
83516 <1% 31,205 $369K
81329 <1% 14,638 $349K
86677 <1% 25,326 $338K
86361 <1% 26,813 $329K
86704 <1% 54,060 $327K
84550 <1% 136,603 $327K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 6,885 $325K
82627 <1% 26,699 $315K
83021 <1% 26,676 $315K
83020 <1% 41,675 $314K
82951 <1% 41,633 $310K
87625 <1% 16,520 $310K
85660 <1% 85,224 $305K
86147 <1% 9,324 $283K
80164 <1% 44,738 $283K
87900 <1% 4,126 $269K
83498 <1% 21,241 $265K
86160 <1% 22,215 $253K
85652 <1% 169,872 $253K
86364 <1% 29,572 $250K
86225 <1% 35,972 $246K
83690 <1% 64,998 $243K
86431 <1% 83,086 $235K
86708 <1% 34,342 $216K
82947 <1% 102,397 $215K
87480 <1% 20,410 $215K
80076 <1% 52,994 $212K
87075 <1% 40,622 $210K
87510 <1% 20,378 $210K
82248 <1% 79,682 $207K
87660 <1% 19,940 $206K
84270 <1% 21,459 $205K
86800 <1% 28,389 $205K
82105 <1% 29,631 $201K
82150 <1% 57,750 $200K
84681 <1% 23,842 $193K
82274 <1% 20,533 $189K
86870 <1% 12,638 $187K
85610 <1% 95,907 $186K
84450 <1% 80,639 $181K
82565 <1% 83,051 $181K
82785 <1% 23,816 $180K
87209 <1% 17,369 $175K
86258 <1% 16,538 $170K
86200 <1% 28,060 $168K
80069 <1% 42,117 $168K
82533 <1% 19,013 $162K
84156 <1% 81,080 $160K
84460 <1% 63,807 $159K
81257 <1% 4,519 $157K
87906 <1% 2,347 $156K
86356 <1% 4,951 $155K
85018 <1% 89,598 $153K
82977 <1% 51,296 $150K
83615 <1% 51,531 $146K
81596 <1% 6,469 $144K
86664 <1% 15,728 $143K
85730 <1% 54,842 $143K
87255 <1% 8,963 $142K
82550 <1% 40,605 $140K
85045 <1% 64,204 $138K
87529 <1% 7,585 $133K
86141 <1% 24,750 $132K
82247 <1% 61,255 $132K
86317 <1% 15,815 $132K
86901 <1% 64,930 $129K
82024 <1% 6,406 $124K
84520 <1% 68,881 $122K
86231 <1% 20,537 $120K
86900 <1% 64,844 $117K
87535 <1% 8,154 $116K
85014 <1% 63,949 $115K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 1,024 $110K
81361 <1% 4,532 $110K
81003 <1% 83,366 $105K
86593 <1% 43,090 $105K
84703 <1% 24,767 $105K
84075 <1% 55,807 $104K
84100 <1% 54,330 $103K
82040 <1% 55,544 $101K
84425 <1% 10,880 $99K
87427 <1% 15,067 $99K
87517 <1% 4,572 $98K
86255 <1% 17,078 $98K
86146 <1% 4,050 $97K
82672 <1% 9,594 $95K
82652 <1% 8,826 $94K
82952 <1% 38,803 $93K
82310 <1% 50,341 $93K
86359 <1% 5,576 $91K
84295 <1% 45,180 $89K
86618 <1% 9,517 $89K
84155 <1% 55,053 $88K
87177 <1% 17,513 $85K
87045 <1% 15,039 $81K
86735 <1% 11,278 $80K
84132 <1% 38,929 $80K
86765 <1% 11,644 $80K
86709 <1% 13,757 $79K
84445 <1% 4,147 $79K
82435 <1% 44,406 $76K
84154 <1% 9,778 $75K
84165 <1% 15,285 $75K
86008 <1% 10,217 $72K
81479 Unlisted molecular pathology procedure <1% 1,789 $72K
86334 <1% 7,768 $70K
87521 Neg quan hep c or qual rna <1% 3,787 $68K
88342 <1% 1,963 $67K
82378 <1% 9,148 $66K
80178 <1% 20,132 $65K
86702 <1% 10,780 $63K
85384 <1% 15,430 $63K
80185 <1% 9,912 $62K
83704 <1% 9,102 $61K
84466 <1% 10,999 $58K
80051 <1% 19,468 $58K
87046 <1% 15,234 $57K
86757 <1% 5,428 $57K
82465 <1% 23,425 $55K
86663 <1% 6,791 $55K
86341 <1% 4,353 $54K
81243 <1% 8,783 $54K
87563 <1% 3,319 $54K
84305 <1% 5,562 $53K
86705 <1% 7,543 $51K
82626 <1% 4,093 $51K
86645 <1% 5,586 $51K
82677 <1% 4,501 $51K
88112 <1% 1,659 $51K
82140 <1% 7,744 $51K
87324 <1% 8,142 $50K
81374 <1% 3,467 $50K
86694 <1% 6,238 $50K
85379 <1% 9,853 $49K
81255 <1% 4,540 $49K
86644 <1% 6,287 $49K
80177 <1% 9,782 $49K
83520 <1% 7,748 $49K
81251 <1% 4,535 $48K
86300 <1% 4,162 $48K
82103 <1% 7,714 $47K
84207 <1% 4,424 $46K
87650 <1% 3,954 $46K
87184 <1% 9,945 $45K
83090 <1% 7,137 $44K
81200 <1% 4,533 $44K
86304 <1% 9,314 $44K
81330 <1% 4,534 $43K
87350 <1% 7,208 $42K
80197 <1% 9,195 $42K
86777 <1% 5,280 $42K
86701 <1% 10,372 $41K
82397 <1% 7,505 $41K
84134 <1% 7,464 $41K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 1,242 $40K
81260 <1% 4,538 $40K
80348 <1% 9,910 $40K
82390 <1% 7,620 $39K
82239 <1% 4,383 $39K
85041 <1% 16,988 $38K
80156 <1% 6,299 $38K
81290 <1% 4,533 $38K
82330 <1% 8,190 $38K
82088 <1% 2,018 $37K
86060 <1% 8,675 $37K
81242 <1% 4,541 $37K
81209 <1% 4,541 $36K
86707 <1% 5,947 $36K
87329 <1% 5,221 $35K
83721 <1% 9,755 $35K
80299 <1% 1,982 $34K
81025 <1% 9,040 $34K
88307 <1% 288 $33K
88312 <1% 1,133 $33K
85048 <1% 18,690 $33K
86336 <1% 4,541 $33K
83718 <1% 7,210 $32K
86381 <1% 3,448 $31K
88304 <1% 1,661 $30K
87493 <1% 2,616 $30K
87101 <1% 6,456 $30K
80361 <1% 10,639 $29K
82985 <1% 3,608 $28K
86256 <1% 3,629 $28K
84484 <1% 4,872 $28K
84432 <1% 3,460 $27K
84166 <1% 3,758 $26K
82575 <1% 4,430 $26K
80349 <1% 2,065 $26K
86301 <1% 3,994 $25K
83521 <1% 2,466 $25K
82553 <1% 3,684 $24K
83921 <1% 3,202 $23K
80365 <1% 10,247 $23K
82374 <1% 13,319 $23K
87040 <1% 3,797 $22K
82731 <1% 538 $22K
83010 <1% 3,843 $22K
87338 <1% 3,319 $22K
82166 <1% 1,423 $22K
83883 <1% 4,521 $21K
82787 <1% 1,679 $20K
87109 <1% 3,106 $20K
82157 <1% 1,317 $20K
80346 <1% 2,221 $20K
84244 <1% 1,957 $20K
86778 <1% 2,594 $20K
87538 <1% 1,568 $19K
85060 <1% 5,777 $19K
82104 <1% 3,068 $19K
80159 <1% 2,974 $19K
80353 <1% 10,202 $19K
83993 <1% 2,205 $18K
84478 <1% 7,464 $18K
86308 <1% 5,541 $18K
84482 <1% 3,946 $18K
84630 <1% 3,829 $18K
80184 <1% 3,679 $18K
85598 <1% 2,504 $18K
85613 <1% 3,779 $17K
87799 <1% 2,069 $17K
86015 <1% 3,666 $17K
80183 <1% 3,459 $17K
85004 <1% 4,525 $17K
82525 <1% 3,529 $17K
84999 <1% 3,069 $17K
80373 <1% 9,708 $17K
80358 <1% 9,746 $16K
85246 <1% 1,309 $16K
87205 <1% 7,686 $16K
85240 <1% 1,619 $16K
82164 <1% 2,682 $16K
80345 <1% 1,459 $16K
86337 <1% 1,502 $15K
80165 <1% 2,651 $15K
82747 <1% 2,333 $15K
81422 <1% 897 $14K
86671 <1% 1,772 $14K
86617 <1% 1,417 $14K
80359 <1% 9,741 $14K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 493 $14K
85007 <1% 8,832 $13K
86037 <1% 1,561 $13K
85245 <1% 1,028 $13K
86335 <1% 1,868 $13K
G0307 Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) <1% 9,052 $12K
81241 <1% 1,624 $12K
80175 <1% 2,847 $12K
80354 <1% 9,280 $12K
84080 <1% 2,187 $12K
88230 <1% 254 $12K
88262 <1% 226 $12K
85597 <1% 1,633 $12K
G0475 Hiv antigen/antibody, combination assay, screening <1% 4,889 $11K
89055 <1% 4,829 $11K
84590 <1% 2,340 $11K
80162 <1% 2,517 $11K
81291 <1% 1,375 $10K
83789 <1% 968 $10K
86666 <1% 989 $10K
81377 <1% 255 $10K
85306 <1% 1,153 $10K
81381 <1% 1,868 $10K
87076 <1% 1,990 $10K
82955 <1% 1,896 $10K
87206 <1% 3,468 $10K
82679 <1% 829 $9K
88341 <1% 184 $9K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 481 $9K
83992 <1% 6,173 $9K
80372 <1% 8,797 $9K
87210 <1% 2,961 $8K
80324 <1% 4,268 $8K
82552 <1% 1,065 $8K
87328 <1% 1,126 $8K
87497 <1% 723 $8K
80202 <1% 1,075 $8K
82653 <1% 820 $8K
82085 <1% 2,199 $8K
87481 <1% 444 $7K
83527 <1% 1,382 $7K
84410 <1% 457 $7K
86162 <1% 745 $7K
84446 <1% 1,225 $7K
83930 <1% 1,712 $7K
82340 <1% 1,960 $6K
82705 <1% 2,139 $6K
83695 <1% 1,393 $5K
85670 <1% 2,270 $5K
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 11,524 $5K
83935 <1% 1,563 $5K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 271 $5K
87106 <1% 878 $5K
80367 <1% 6,107 $5K
83014 <1% 1,248 $5K
82610 <1% 678 $5K
85049 <1% 2,152 $5K
86357 <1% 255 $5K
86747 <1% 343 $5K
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 8,115 $5K
85732 <1% 1,172 $5K
81401 <1% 1,042 $5K
87015 <1% 1,367 $4K
87116 <1% 1,059 $4K
81240 <1% 665 $4K
87425 <1% 419 $4K
80347 <1% 7,911 $4K
86355 <1% 194 $4K
84300 <1% 1,577 $4K
84163 <1% 356 $4K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 21,343 $3K
85303 <1% 562 $3K
81383 <1% 105 $3K
86036 <1% 677 $3K
82172 <1% 3,587 $3K
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count <1% 1,765 $3K
80356 <1% 689 $3K
83835 <1% 374 $3K
85300 <1% 590 $3K
80337 <1% 5,693 $3K
83874 <1% 514 $3K
80370 <1% 7,867 $3K
80338 <1% 5,695 $3K
80368 <1% 5,722 $3K
80360 <1% 5,711 $2K
80334 <1% 5,703 $2K
80377 <1% 5,679 $2K
80235 <1% 367 $2K
84252 <1% 262 $2K
80326 <1% 5,671 $2K
80364 <1% 5,667 $2K
80341 <1% 5,667 $2K
80331 <1% 5,667 $2K
80371 <1% 5,670 $2K
80344 <1% 5,680 $2K
82668 <1% 381 $2K
81517 <1% 32 $2K
80366 <1% 5,686 $2K
87254 <1% 218 $2K
80357 <1% 5,664 $2K
81490 <1% 268 $2K
82542 <1% 221 $2K
84152 <1% 251 $2K
80320 <1% 179 $2K
82232 <1% 404 $2K
86631 <1% 294 $2K
87420 <1% 213 $2K
87807 <1% 216 $2K
80355 <1% 5,659 $2K
83003 <1% 226 $2K
86880 <1% 717 $2K
86005 <1% 608 $2K
82180 <1% 391 $2K
86753 <1% 233 $1K
83625 <1% 213 $1K
80369 <1% 347 $1K
80201 <1% 305 $1K
80362 <1% 430 $1K
84145 <1% 194 $1K
80230 <1% 79 $1K
85305 <1% 228 $1K
86148 <1% 360 $981.39
84202 <1% 102 $978.87
80198 <1% 133 $925.62
86738 <1% 58 $907.84
80203 <1% 177 $830.65
81015 <1% 640 $785.36
82308 <1% 52 $696.43
85302 <1% 150 $676.31
84597 <1% 98 $650.41
80145 <1% 73 $637.27
83937 <1% 41 $574.21
89060 <1% 133 $548.36
83631 <1% 149 $536.95
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 72 $528.15
88300 <1% 72 $470.53
84206 <1% 31 $411.67
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 3,244 $348.32
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 1,113 $318.41
86804 <1% 64 $302.47
89051 <1% 85 $298.98
85307 <1% 50 $291.13
86849 <1% 64 $268.81
G0124 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician <1% 1,568 $264.97
86215 <1% 49 $255.49
87230 <1% 28 $253.69
87476 <1% 18 $246.17
82384 <1% 35 $243.04
81283 <1% 13 $232.34
82681 <1% 41 $228.35
82175 <1% 21 $226.25
85046 <1% 44 $183.69
83825 <1% 21 $180.15
84181 <1% 81 $168.55
86703 <1% 40 $136.35
84133 <1% 52 $128.32
81256 <1% 15 $118.86
83986 <1% 56 $117.25
84140 <1% 20 $113.74
85705 <1% 32 $103.75
82595 <1% 47 $98.48
84433 <1% 17 $97.84
80342 <1% 14 $94.19
86790 <1% 37 $90.26
83605 <1% 20 $85.37
80323 <1% 12 $84.89
80158 <1% 32 $68.35
84591 <1% 20 $43.28
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 188 $40.50
36416 <1% 6,062 $26.15
S3600 Stat laboratory request (situations other than s3601) <1% 4,029 $17.74
99199 Unlisted special service, procedure or report <1% 128 $10.32
81002 <1% 1,328 $6.75
83698 0% 38 $0.00
P9604 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge 0% 50 $0.00
P9603 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled 0% 492 $0.00
99422 0% 14 $0.00
80374 0% 15 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWILLIAMS, KIMBERLY (VP)
Same official

Other billing entities under WILLIAMS, KIMBERLY

Full network →
ProviderLocationPaid
Laboratory Corporation of America HoldingsBurlington, NC$1.44B
Laboratory Corporation of America HoldingsRaritan, NJ$717.47M
Laboratory Corporation of America HoldingsDublin, OH$617.02M
Laboratory Corporation of AmericaPhoenix, AZ$265.90M
Laboratory Corporation of America HoldingsBurlington, NC$264.26M
Laboratory Corporation of America HoldingsCharleston, WV$220.04M
Laboratory Corporation of AmericaSeattle, WA$186.69M
Laboratory Corporation of AmericaTampa, FL$171.13M
Laboratory Corporation of AmericaSan Diego, CA$147.14M
Laboratory Corporation of AmericaHouston, TX$103.81M
Laboratory Corporation of AmericaEnglewood, CO$77.80M
Laboratory Corporation of AmericaDallas, TX$77.42M
Laboratory Corporation of AmericaBurlington, NC$59.75M
Medtox Laboratories, INCSaint Paul, MN$47.72M
Laboratory Corporation of America HoldingsBurlington, NC$15.65M
Laboratory Corporation of AmericaSan Antonio, TX$11.67M
Tri-Cities Laboratory, LLCKennewick, WA$8.69M
Laboratory Corporation of America HoldingsMonroe, LA$3.39M
Laboratory Corporation of AmericaItasca, IL$3.37M
Laboratory Corporation of AmericaAlbany, NY$2.06M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.